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Abstract	  
Introduction	  The	   primary	   function	   of	   the	   contractile	   vascular	   smooth	   muscle	   cells	   (cVSMCs)	   is	   the	  regulation	  of	  the	  vascular	  contractility	  which	  	  means	  the	  adaptation	  of	  the	  vascular	  tonus	  in	  response	   to	   the	   modulation	   of	   the	   blood	   pressure	   and	   blood	   flow.	   The	   cVSMCs	   are	  essentially	   quiescent,	   and	   therefore	   their	   synthesis	   rate	   is	   very	   limited.	   They	   are	  characterized	   by	   the	   expression	   of	   contractile	   proteins	   specific	   to	   the	   muscular	   tissue	  including	  myosin,	  h-­‐caldesmon	  and	  α-­‐smooth	  muscle	  actin	  (α-­‐SMA).	  These	  contractile	  cells	  are	  strongly	  represented	  in	  the	  media	  layer	  of	  the	  arterial	  wall	  and,	  in	  a	  smaller	  proportion,	  of	   the	   vein	   wall.	   Their	   typical	   stretched-­‐out	   morphology	   allows	   recognizing	   them	   by	   a	  histological	   analysis.	   They	   do	   not	   produce	   any	   extracellular	   matrix	   (ECM),	   and	   do	   not	  migrate	  through	  the	  different	  layers	  of	  the	  vessel	  wall,	  and	  are	  not	  directly	  involved	  in	  the	  development	  of	  intimal	  hyperplasia	  (IH).	  Neointimal	  formation	  occurs	  after	  endothelial	  disruption	  leading	  to	  complex	  molecular	  and	  biological	  mechanisms.	  The	  de-­‐differentiation	  of	  cVSMCs	  into	  synthetic	  VSMCs	  (sVSMCs)	  is	  mentioned	  as	   a	  key	  element.	  These	  non	  mature	   cells	   are	  able	   to	  proliferate	  and	  produce	  ECM.	  The	   characterization	   of	   the	   vascular	   smooth	   muscle	   cells	   (VSMCs)	   from	   healthy	   and	  stenosed	   vascular	   tissues	   will	   contribue	   to	   the	   understanding	   of	   the	   different	   biological	  processes	  leading	  to	  IH	  and	  will	  be	  useful	  for	  the	  development	  of	  new	  therapies	  to	  interfere	  with	  the	  cVSMCs	  growth	  and	  migration.	  The	   aim	  of	   our	   research	  was	   to	   quantify	   the	  proportion	  of	   cVSMCs	   and	   sVSMCs	   into	   the	  healthy	  and	  pathologic	  human	  blood	  vessel	  wall	  and	  to	  characterize	  their	  phenotype.	  	  
Methods	  We	   selected	   23	   specimens	   of	   arterial	   and	   venous	   segments	   from	   18	   patients.	   All	   these	  specimens	  were	  stored	  in	  the	  biobank	  from	  the	  thoracic	  and	  vascular	  surgery	  departement.	  4	  groups	  were	  designed	  (group	  1	  :	  arteries	  without	  lesions	  (n=3)	  ;	  group	  2	  :	  veins	  without	  lesions	  (n=1)	  ;	  group	  3	  :	  arteries	  with	  stenosis	  (n=9)	  ;	  group	  4	  :	  veins	  with	  stenosis	  (n=10)).	  Histology	  :	   5µm-­‐sections	   were	   made	   from	   each	   sample	   embedded	   in	   paraffin	   wax	   and	  further	   stained	  with	   hematoxylin	  &	   eosin	   (HE),	   Van	   Gieson’s	   stain	   (VGEL)	   and	  Masson’s	  Trichrome	   (TMB).	   Pathologic	   tissues	  were	   defined	   using	   the	   label	   that	  was	   given	   to	   the	  macroscopic	  samples	  by	  the	  surgeon	  and	  also,	  based	  on	  the	  histological	  analysis	  with	  HE	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and	  VGEL	  evaluating	  the	  presence	  of	  a	  thickened	  intima.	  The	  same	  was	  done	  to	  the	  control	  samples	  evaluating	  the	  absence	  of	  thickening.	  Immunohistochemistry	  :	   The	   primary	   antibodies	   were	   used	  :	   α-­‐SMA,	   vimentin,	   h-­‐caldesmon,	   calponin,	   smooth	   muscle-­‐myosin	   heavy	   chain	   (SM-­‐MHC),	   tropomyosin-­‐4,	  retinol	   binding	   protein-­‐1	   (RBP-­‐1),	   non	   muscle-­‐myosin	   heavy	   chain-­‐B	  (NM-­‐MHC-­‐B),	   Von	  Willebrand	   factor	  (VWF).	  A	   semi-­‐quantitative	   assessment	  of	   the	   intensity	  of	   each	   sample	  stained	  was	  performed.	  Western	  Blot	  :	  Segments	  of	  arteries	  and	  veins	  were	  analyzed	  using	  the	  following	  primary	  antibodies	  :	   α-­‐SMA,	   Calponin,	   SM-­‐MHC,	   NM-­‐MHC-­‐B.	   The	   given	   results	   were	   then	  normalized	  with	  tubulin.	  
Results	  Our	  data	   showed	   that,	  when	  using	   immunohistochemistry	  analysis	  we	   found	   that	  α-­‐SMA	  was	  mostly	  expressed	  in	  control	  arteries,	  whereas	  NM-­‐MHC-­‐B	  in	  the	  pathologic	  ones.	  Using	  SM-­‐MHC,	   calponin,	   vimentin	   and	   caldesmon	  we	   found	   no	   significative	   differences	   in	   the	  expression	   of	   these	   proteins	   in	   the	   control	   and	   in	   the	   pathologic	   samples.	  Western	   Blot	  analysis	   showed	   an	   inverse	   correlation	   between	   healthy	   and	   pathological	   samples	   as	  α-­‐SMA	   was	   more	   expressed	   in	   the	   pathological	   samples,	   while	   NM-­‐MHC-­‐B	   in	   the	   control	  group	  ;	  SM-­‐MHC	  and	  calponin	  were	  mostly	  expressed	  in	  the	  pathologic	  samples.	  
Conclusion	  Our	   study	   showed	  no	   clear	  differences	  between	   stenotic	   and	   control	   arterial	   and	  venous	  segments	   using	   semi-­‐quantitative	   assessement	   by	   immunohistochemistry.	   Western	   Blot	  showed	  a	  significant	  increased	  expression	  of	  	  α-­‐SMA,	  calponin	  and	  SM-­‐MHC	  in	  the	  arteries	  with	  stenosis,	  while	  NM-­‐MHC-­‐B	  was	  mostly	  expressed	  in	  the	  arteries	  without	  lesions.	  Further	  studies	  are	  needed	   to	   track	   the	   lineage	  of	  VSMCs	   to	  understand	   the	  mechanisms	  leading	  to	  IH.	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Introduction	  Peripheral	   arterial	   disease	   reprents	   a	  major	   clinical	   problem	   in	   the	   industrial	   countries.	  There	  are	  about	  200'000	  and	  500'000	  patients	  treated	  for	  this	  medical	  problem	  every	  year	  in	  Europe,	  and	  it	  won’t	  stop	  increasing.1	  Lower	  limb	  revascularization	  by	  a	  surgical	  bypass	  is	  a	  therapeutic	  solution	  that	  is	  often	  used	  despite	  the	  increasing	  number	  of	  endovascular	  interventions.	  Doing	  such	  a	  bypass	   is	  generally	  sufficent	   to	  heal	   intermittent	  claudication	  or	  critical	  limb	  ischemia.2	  	  The	  results	  of	  primary	  and	  secondary	  permeability	  are	  relatively	  good	   in	   a	   short	   to	   mid-­‐term.3	   Nevertheless,	   in	   20-­‐50%	   of	   all	   cases,	   we	   have	   to	   face	  restenosis	   linked	   to	   the	   development	   of	   myointimal	   proliferation	   at	   the	   anastomosis	  and/or	   inside	   the	   bypass.4,5	   Indeed,	   surgical	   or	   endovascular	   interventions	   create	   a	  vascular	  trauma	  triggering	  a	  remodelling	  process	  named	  intimal	  hyperplasia	  (IH).	  It	  can	  be	  sufficient	   to	   create	   a	   significant	   stenosis.6	   IH	   is	   the	   biological	   result	   of	   the	   increasing	  number	  of	  vascular	  smooth	  muscle	  cells	  (VSMCs)	  in	  the	  sub-­‐intima	  region,	  followed	  by	  the	  proliferation	  of	   the	  extra-­‐cellular	  matrix	  (ECM)	  which	  provokes	  a	  thickening	  of	   the	  blood	  vessel	  wall	  and	  thus	  a	  decrease	  of	  the	  lumen.	  VSMCs	  are	  the	  key-­‐cells	  of	  this	  process.	  The	   primary	   function	   of	   the	   contractile	   vascular	   smooth	   muscle	   cells	   (cVSMCs)	   is	   the	  regulation	   of	   the	   vascular	   contractility	   which	  	   means	   adaptation	   of	   the	   vascular	   tonus,	  blood	   pression	   and	   blood	   flow.	   They	   are	   essentially	   quiescent,	   which	   means	   that	   their	  synthesis	   rate	   is	   very	   limited.2	   They	   are	   characterized	   by	   the	   expression	   of	   contractile	  proteins	   specific	   to	   the	   muscular	   tissue	   including	   myosin,	   h-­‐caldesmon	   and	   α-­‐smooth	  muscle	  actin	  (α-­‐SMA).7	  These	  contractile	  cells	  are	  strongly	  represented	  in	  the	  media	  layer	  from	   the	   arterial	   wall	   and,	   in	   a	   smaller	   proportion,	   from	   the	   vein	   wall.8	   Their	   typical	  stretched-­‐out	  morphology	  make	  them	  easy	  to	  recognize	  by	  a	  histological	  analysis.	  They	  do	  not	   produce	   any	   ECM	   (connective	   tissue	  composed	   of	   proteoglycans	   (PG),	   non-­‐PG	  polysaccharides,	   fibers,	   fibronectin	   and	   laminin),	   do	   not	   migrate	   through	   the	   different	  layers	  of	  the	  vessel	  wall,	  and	  are	  not	  directly	  implicated	  into	  the	  IH	  process.2	  	  In	  the	  contrary,	  synthetic	  vascular	  smooth	  muscle	  cells	  (sVSMCs)	  are	  thought	  to	  come	  from	  the	   de-­‐differentiation	   of	   cVSMCs.9,10	   This	   mechanism,	   only	   partially	   understood,	   is	  triggered	   by	   the	   vascular	   trauma	   associated	   with	   an	   endothelial	   injury	   followed	   by	  platelets	   aggregation	   and	   their	   activation.	   A	   complicated	   enzymatic	   cascade	   permits	   the	  phenotypical	  modifications	  of	  VSMCs.4,11	  These	  cells	   can	  migrate	   from	  the	  media	   layer	   to	  the	  intima	  layer.	  They	  also	  have	  a	  very	  high	  proliferation	  rate,	  produce	  ECM	  and	  loose	  their	  vascular	   contractility	   capacity.	   We	   can	   differenciate	   them	   from	   the	   cVSMCs	   by	   the	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expression	  of	  diverse	  proteins	  like	  non-­‐muscle	  myosin	  heavy	  chain	  (NM-­‐MHC)	  and	  retinol	  binding	  protein-­‐1	  (RBP-­‐1).7,12	  The	   conversion	   of	   cVSMCs	   into	   sVSMCs	   is	   thought	   to	   play	   a	   major	   role	   in	   the	   vascular	  diseases	  such	  as	  atherosclerosis	  and	  restenosis.13-­‐15	  Most	  of	  the	  new	  therapies	  are	  centered	  on	  the	  aspect	  of	  de-­‐differentiation	  of	  these	  cVSMCs	  into	  sVSMCs	  in	  the	  context	  of	  vascular	  lesions	  in	  order	  to	  significantly	  inhibit	  this	  biological	  process	  of	  IH.16	  Nevertheless,	  the	  origin	  of	  sVSMCs	  is	  controversial,	  and	  the	  specific	  markers	  are	  lacking	  to	  trace	  the	  lineage	  of	  VSMCs.17	  	  The	  evaluation	  of	   the	  proportion	  of	  VSMCs	   in	  healthy	  and	  stenosed	  vascular	  wall	  will	  be	  useful	   for	   the	   development	   of	   future	   new	   therapies	   focused	   on	   the	   de-­‐differentiation	   of	  cVSMCs	  into	  sVSMCs.	  The	  aim	  of	   this	   research	  was	   to	  quantify	   the	  proportion	  of	   cVSMCs	  and	   sVSMCs	   into	   the	  healthy	  and	  pathologic	  human	  blood	  vessel	  wall	  and	  characterize	  their	  phenotype.	  
	  
Methods	  
Tissue	  sampling	   	  The	  human	  veins	  and	  arteries	  were	  harversted	  during	  surgical	   interventions.	  The	  ethical	  committee	  of	  the	  University	  Hospital	  of	  Lausanne	  approved	  the	  experiments,	  which	  are	  in	  accordance	  with	   the	   principles	   outlined	   in	   the	   Declaration	   of	   Helsinki	   for	   use	   of	   human	  tissue.	  The	   tissue	   fragments	  were	   then	  divided	   into	   two	  equal	   lengths.	  One	   segment	  was	  directly	  fixed	  in	  formol	  and	  the	  other	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  The	  specimens	  were	  characterized	  and	  described	  into	  an	  anonymised	  database.	  The	  selected	  samples	  were	  divided	  in	  four	  groups	  :	  
• Group	  1	  :	  Arteries	  without	  lesions	  (named	  control	  arteries)	  (n=3)	  
• Group	  2	  :	  Veins	  without	  lesions	  (named	  control	  vein)	  (n=1)	  
• Group	  3	  :	  Arteries	  with	  stenosis	  (named	  pathologic	  arteries)	  (n=9)	  
• Group	  4	  :	  Veins	  with	  stenosis	  (named	  pathologic	  veins)	  (n=10)	  A	  total	  of	  23	  specimens	  were	  harvested	  in	  18	  patients.	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Histology	  The	  different	  samples	  were	  first	  embedded	  in	  paraffin	  wax	  and	  consecutive	  5µm-­‐sections	  were	  made	  on	  each	  sample.	  The	   sections	  were	   further	   stained	  with	  hematoxylin	  &	  eosin	  (HE),	  Van	  Gieson’s	  stain	  (VGEL)	  and	  Masson’s	  Trichrome	  (TMB).	  HE	  will	  stain	  the	  nucleus	  in	  black/purple	  and	  the	  different	  cytoplasmic	  components	  in	  pink/red	  ;	  VGEL	  will	  stain	  the	  collagen	  fibers	  in	  red,	  in	  order	  to	  differentiate	  the	  different	  layers	  of	  the	  blood	  vessel	  wall	  as	  well	  as	  the	  presence	  of	  IH	  ;	  TMB	  will	  differentiate	  the	  connective	  tissue	  stained	  in	  blue	  from	  the	  nucleus	  (dark	  red/purple)	  and	  the	  cytoplasm	  stained	  in	  red/pink.	  Among	  the	  30	  samples	  initially	  chosen,	  we	  selected,	  based	  on	  the	  HE	  and	  VGEL	  stainings,	  the	  best	  samples	  for	  the	  immunohistochemistry	  analysis,	  7	  samples	  from	  the	  30	  were	  dicarded.	  This	  brings	  the	  count	  to	  23	  samples	  used	  as	  listed	  in	  the	  groups	  above.	  Pathologic	   tissues	   were	   defined	   first,	   using	   the	   label	   that	   was	   given	   to	   the	  macroscopic	  sample	  by	   the	   surgeon	  and	  second,	  based	  on	   the	  histological	   analysis	  with	  HE	  and	  VGEL	  evaluating	  the	  presence	  of	  a	  thickened	  intima.	  The	  same	  was	  done	  to	  the	  control	  samples	  evaluating	  the	  absence	  of	  thickening.	  
Immunohistochemistry	  The	  primary	   antibodies	   listed	   below	  were	   used.	   Binding	   sites	   of	   the	   different	   antibodies	  were	  visualized	  using	  an	  avidin-­‐biotinylated	  horseradish	  peroxidase	   complex	   (Vectastain	  Elite	   ABC	   Kit,	   USA).	   After	   rinsing	   the	   sections	   in	   PBS,	   the	   precipitate	   obtained	   from	   the	  perdoxidase	  reaction	  was	  visualized	  using	  0.1%	  3,3-­‐diaminobenzidine	  tetrahydrochloride	  dehydrate,	   dissolved	   in	   PBS	   containing	   0.3%	  H2O2.	   Antibody	   binding	  was	   revealed	   using	  the	  avidin-­‐biotin	  technique.	  Antibodies	  used	  in	  the	  study	  :	  1. α-­‐SMA	  (α-­‐Smooth	  Muscle	  Actin	  ;	  Sigma	  ;	  1:50’000)	  2. Vimentin	  (Dako	  ;	  1:200)	  3. H-­‐Caldesmon	  (Dako	  ;	  1:100)	  4. Calponin	  (Dako	  ;	  1:200)	  5. SM-­‐MHC	  (Smooth	  Muscle-­‐Myosin	  Heavy	  Chain	  ;	  Milipore	  ;	  1:200)	  6. Tropomyosin-­‐4	  (Serotec	  ;	  1:100)	  7. RBP-­‐1	  (Retinol	  Binding	  Protein-­‐1	  ;	  Abnova	  ;	  1:50)	  8. NM-­‐MHC-­‐B	  (Non	  Muscle-­‐Myosin	  Heavy	  Chain-­‐B	  ;	  Abcam	  ;	  1:100)	  9. VWF	  (Von	  Willebrand	  Factor	  ;	  Dako	  ;	  1:500)	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Then	   a	   semi-­‐quantitative	   assessment	   of	   the	   intensity	   of	   each	   sample	   stained	   was	  performed.	  	  An	  arbitrary	  scale	  was	  used	  :	  (0)	  :	  no	  expression	  ;	  (+)	  :	  light	  expression	  ;	  (++)	  :	  moderate	  expression	  ;	  (+++)	  :	  strong	  expression.	  The	  sections	  were	  analysed	  at	  3	  different	  time	  frame	  by	  the	  same	  author	  each	  and	  every	  time.	  Then	  a	  mean	  value	  was	  calculated	  on	  the	  basis	  of	  these	  3	  evaluations.	  
Western	  Blot	  Segments	  of	  veins	  and	  arteries	  were	  reduced	  to	  powder	  and	  homogenized	  in	  lysis	  buffer	  as	  published.	  Samples	  of	  total	  vessel	  extracts	  (25µg)	  were	  resolved	  by	  SDS-­‐PAGE	  (10%)	  and	  transferred	  to	  a	  polyviliden	  difluoride	  membrane	  (immobilon	  p,	  Millipore).	  The	  membrane	  was	   incubated	   with	   a	   primary	   antibody	   overnight	   at	   4°C,	   washed	   in	   PBS-­‐T	   3	   times	   10	  minutes	   and	   then	   incubated	   for	  1h	  with	  horseradish	  peroxydase-­‐linked	  antibody	  against	  mouse	   (Southern	   Biotech),	   rabbit	   (Thermo	   Scientific)	   or	   goat	   IgGs	   (Sigma),	   whichever	  adequate.	   Immunostaining	   was	   revealed	   by	   chemoluminescence,	   using	   ECL-­‐plus	   kit	   (GE	  Healthcare).	  The	  following	  primary	  antibodies	  were	  used	  :	  1. α-­‐SMA	  (Sigma	  ;	  1:5’000)	  2. SM-­‐MHC	  (Milipore	  ;	  1:1’000)	  	  3. Calponin	  (Dako	  ;	  1:2’000)	  4. NM-­‐MHC-­‐B	  	  (Abcam	  ;	  1:2’000)	  
	  
Results	  
Patients	  Characteristics	  Table	  1	  summarizes	  the	  demographic	  and	  clinical	  data	  characteristics	  of	  the	  patients	  in	  the	  four	   groups.	   All	   clinical	   data	   are	   based	   on	   the	   23	   samples	   used	   for	   the	  immunohistochemistry	  analysis;	  therefore,	  we	  had	  14	  men	  samples	  and	  9	  women	  samples	  (mean	   age	  :	   67.5	   ±	   14.3	   years).	   A	   particular	   attention	   was	   taken	   to	   list	   the	   different	  comorbidities	  and	  their	  medical	  treatements.	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Table	   1.	   Demographic	   &	   Clinical	   Data.	   (CVD)	  :	   cardiovascular	   disease	  ;	   (CDK)	  :	   chronic	   kidney	   disease	  ;	  (SD)	  :	  standard	  deviation.	  	  We	  can	  observe	  (Figure	  1)	   that	  100%	  of	   the	  pathologic	  arteries	  are	   from	  the	   lower	   limb,	  whereas	  100%	  of	   the	  pathologic	   veins	   originate	   from	   the	  upper	   limb.	  And	   all	   pathologic	  arteries	  come	  from	  the	  external	  iliac	  artery.	  	  
	  
Figure	   1.	   Anatomic	   Origins	   of	   Vascular	   Segments.	   Simplified	   anatomic	   plan	   showing	   the	   origins	   of	   the	  different	  vascular	   segments	   listed,	  with	   for	  each	  origin,	   the	  number	  of	  pathologic	  and	  control	   samples	   that	  were	  harvested	  from	  (number	  of	   pathologic	   samples/number	  of	   control	   samples).	  For	  example	  :	  (5/0)	  CV	  means	  5	  pathologic	   samples	   and	  0	   control	   sample	  harvested	   from	   the	   cephalic	   vein.	   (SFA)	  :	   superficial	  femoral	  artery	  ;	  (DFA)	  :	  deep	  femoral	  artery	  ;	  (CFA)	  :	  common	  femoral	  artery	  ;	  (PTA)	  :	  posterior	  tibial	  artery	  ;	  (TFT)	  :	  tibio-­‐fibular	  trunk	  ;	  (EIA)	  :	  external	  iliac	  artery	  ;	  (CV)	  cephalic	  vein	  ;	  (BV)	  :	  basilic	  vein	  ;	  (GSV)	  :	  great	  saphenous	  vein.	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Histology	  The	  sections	  of	  arteries	  and	  veins	   from	  control	  and	  pathologic	  vessels,	  were	   first	   stained	  with	  the	  standard	  immunostainings	  (Figures	  2	  &	  3),	  to	  visualize	  the	  different	  layers	  of	  the	  vessel	  wall,	  which	  also	  permitted	  to	  categorize	  them	  into	  the	  control	  or	  pathologic	  groups.	  	  The	  Figures	  2	  &	  3,	  comparing	  respectively	  a	  control	  artery	  with	  a	  pathologic	  artery	  (Figure	  2)	  and	  a	  control	  vein	  with	  a	  pathologic	  vein	  (Figure	  3)	  stained	  for	  the	  standard	  histological	  exam,	  show,	  in	  the	  control	  group,	  a	  better	  organized	  architecture	  of	  the	  vessel	  wall	  than	  in	  the	   pathologic	   one.	   It	   also	   shows	   the	   presence	   of	   a	   thickened	   intima	   in	   the	   pathologic	  group,	  which	  is	  typical	  of	  IH.	  	  While	  selecting	  the	  samples,	  the	  «	  best	  »	  ones	  corresponding	  to	  each	  group	  were	  selected.	  By	   «	  best	  »,	   we	  mean	  most	   appropriate	   to	   the	   group	   description	  ;	   for	   example	  a	   control	  sample	  would	  be	  a	  vein	  or	  an	  artery	  without	  a	  thickened	  intima.	  Note	  that	  the	  control	  vein	  does	  not	  fit	  the	  criterias	  as	  perfectly	  as	  the	  control	  artery	  does	  due	  to	  the	  light	  presence	  of	  IH	  ;	  we	  had	   to	   face	  some	  availability	   troubles	  concerning	   the	  healthy	  veins.	  So	  we	  had	   to	  choose	  the	  «	  healthiest	  »	  one.	  TMB	   will	   differentiate	   the	   connective	   tissue	   stained	   in	   blue	   from	   the	   nucleus	   (dark	  red/purple)	   and	   the	   cytoplasm	   stained	   in	   red/pink.	   Compared	   to	   the	   control	   group,	   the	  pathologic	   one	   shows	   a	   slight	   predominance	   of	   blue	   into	   the	   intima,	   for	   both	   veins	   and	  arteries.	  VWF	   staining	   was	   included	   in	   the	   standard	   histological	   exam	   figures,	   although	   it	   is	   a	  immunohistochemical	   staining,	   because	   it	   allows	   to	   see	   the	   continuity	   of	   the	   vascular	  endothelium	  of	  the	  lumen.	  It	  was	  important	  in	  this	  study,	  to	  assess	  if	  the	  endothelium	  was	  preserved	  despite	  the	  IH	  ;	  and	  as	  shown	  in	  Figures	  2	  &	  3,	  it	  is	  somehow	  well	  preserved	  in	  each	  sample	  stained,	  a	  bit	  thinner	  or	  less	  expressed	  in	  the	  pathologic	  group.	  	  	  	  





Figure	  2.	  Healthy	  vs	  Pathologic	  Artery,	  original	  magnification	  x5.	  (A-­‐D)	  :	  control,	  healthy	  artery	  ;	  (E-­‐H)	  :	  pathologic,	   stenosed	   artery	  ;	   (VGEL)	  :	   Van	   Gieson’s	   stain	  ;	   (HE)	   Hematoxylin	   &	   Eosin	   stain	  ;	   (VWF)	  :	   Von	  Willebrand	  Factor	  stain	  ;	  (TMB)	  Masson’s	  Trichrome	  ;	  (L)	  :	  lumen	  ;	  (I)	  :	  intima	  ;	  (M)	  :	  media	  ;	  (A)	  :	  adventitia.	  	  





Figure	   3.	   Healthy	   vs	   Pathologic	   Vein,	   original	   magnification	   x5.	   (A-­‐D)	  :	   control,	   healthy	   vein	   ;	   (E-­‐H)	  :	  pathologic,	   stenosed	   vein.	   (VGEL)	  :	   Van	   Gieson’s	   stain	  ;	   (HE)	   Hematoxylin	   &	   Eosin	   stain	  ;	   (VWF)	  :	   Von	  Willebrand	  Factor	  stain	  ;	  (TMB)	  :	  Masson’s	  Trichrome	  ;	  (L)	  :	  lumen	  ;	  (I)	  :	  intima	  ;	  (M)	  :	  media	  ;	  (A)	  :	  adventitia.	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Figure	  4.	  Healthy	  vs	  Pathologic	  Arteries	  with	   the	  Primary	  Antibodies	  Tested,	  original	  magnification	  
x5.	   (α-­‐SMA)	  :	   α-­‐Smooth	  Muscle	   Actin	  ;	   (Calp)	  :	   Calponin	  ;	   (Cald)	  :	   H-­‐Caldesmon	  ;	   (RBP1)	  :	   Retinol	   Binding	  Protein-­‐1	  ;	  (Vim)	  :	  Vimentin	  ;	  (NMMHC)	  :	  Non-­‐Muscle	  Myosin	  Heavy	  Chain	  ;	  (MHC)	  :	  Smooth-­‐Muscle	  Myosin	  Heavy	  Chain	  ;	  (Tropo)	  :	  Tropomyosin-­‐4	  ;	  (L)	  :	  lumen	  ;	  (I)	  :	  intima	  ;	  (M)	  :	  media	  ;	  (A)	  :	  adventitia.	  The	  first	  and	  the	  third	  column	  (A,	  C,	  E,	  G,	  I,	  K,	  M,	  O)	  represent	  the	  control	  artery.	  The	  second	  and	  last	  column	  (B,	  D,	  F,	  H,	  J,	  
L,	  N,	  P)	  represent	  the	  pathologic	  artery.	  	  
	  
Table	  2.	  Semi-­‐quantitative	  Assessment	  of	  the	  Expression	  of	  the	  Antibodies	  with	  Immunohistochemical	  
analysis.	  (0)	  :	  no	  expression	  ;	  (+)	  :	  light	  expression	  ;	  (++)	  :	  moderate	  expression	  ;	  (+++)	  :	  strong	  expression.	  





Figure	  5.	  Healthy	  vs	  Pathologic	  Veins	  with	  the	  Primary	  Antibodies	  Tested,	  original	  magnification	  x5.	  (α-­‐SMA)	  :	   α-­‐Smooth	   Muscle	   Actin	  ;	   (Calp)	  :	   Calponin	  ;	   (Cald)	  :	   H-­‐Caldesmon	  ;	   (RBP1)	  :	   Retinol	   Binding	  Protein-­‐1	  ;	  (Vim)	  :	  Vimentin	  ;	  (NMMHC)	  :	  Non-­‐Muscle	  Myosin	  Heavy	  Chain	  ;	  (MHC)	  :	  Smooth-­‐Muscle	  Myosin	  Heavy	  Chain	  ;	  (Tropo)	  :	  Tropomyosin-­‐4	  ;	  (L)	  :	  lumen	  ;	  (I)	  :	  intima	  ;	  (M)	  :	  media	  ;	  (A)	  :	  adventitia.	  The	  first	  and	  the	  third	  column	  (A,	  C,	  E,	  G,	  I,	  K,	  M,	  O)	  represent	  the	  control	  vein.	  The	  second	  and	  last	  column	  (B,	  D,	  F,	  H,	  J,	  L,	  
N,	  P)	  represent	  the	  pathologic	  vein.	  	  Based	   on	   the	   immunohistochemical	   analysis	   of	   the	   samples	   above,	   a	   semi-­‐quantitative	  assessment	  of	  the	  intensity	  was	  performed	  (Table	  2):	  	  The	  major	  differences	  that	  can	  be	  observed,	  are	  the	  antibodies’	  expressions	  between	  each	  group	   stained	   with	   tropomyosin-­‐4	   and	   NM-­‐MHC-­‐B	   in	   both	   group	   veins	   and	   arteries.	  Indeed,	   comparing	   stainings	   with	   tropomyosin-­‐4	   and	   NM-­‐MHC-­‐B,	   the	   differences	   in	  expression	  between	  the	  pathologic	  and	  control	  artery	  are	  the	  same	  :	  the	  pathologic	  artery	  has	   a	   light	   expression,	   while	   the	   control	   one	   has	   no	   expression.	   Concerning	   the	   veins’	  groups	  :	   the	   pathologic	   vein	   has	   for	   both	   tropomyosin-­‐4	   and	   NM-­‐MHC-­‐B	   stainings	   a	  moderate	   expression,	   whereas	   control	   vein	   has	   no	   expression	   when	   stained	   with	  tropomyosin-­‐4	  and	  a	   light	  expression	  when	  stained	  with	  NM-­‐MHC-­‐B.	  Note	   that	  SMA	  was	  mostly	  expressed	  in	  the	  control	  artery,	  whereas	  NM-­‐MHC-­‐B	  in	  the	  pathologic	  one.	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Western	  Blot	  Figure	  6	  shows	  the	  WB	  of	  the	  antibodies	  listed	  above	  tested	  on	  the	  arteries.	  There	  was	  only	  one	  control	  vein,	  therefore	  we	  did	  not	  do	  a	  WB	  analysis	  on	  the	  veins.	  It	  is	  a	  semi-­‐quantitative	  assessment	  showing	  the	  differences	  in	  expression	  of	  the	  antibodies	  tested,	  normalized	  with	  a	  commonly	  used	  antibody	  (tubulin).	  It	  showed	  that	  the	  expression	  of	  SMA,	  SM-­‐MHC	  and	  calponin	  were	  much	  stronger	  into	  the	  pathological	  group	  compared	  to	   control.	   Concerning	  NM-­‐MHC-­‐B,	   it	  was	  more	   expressed	   into	   the	   control	   group	   than	   in	  pathologic.	  	  	  
A	   	   	   	   	   	   	   B	  
SMA 	  	  SM-­‐MHC
Tub 	  	  	  	  	  	  	  	  	  	  	  Tub 	  
	   	  	  
C	   	   	   	   	   	   	   D	  
Calp 	  	  NM-­‐MHC
Tub 	   Tub 	  
	   	  
Figure	   6.	   Western	   blots	   analysis.	   This	   analysis	   and	   the	   results	   shown	   were	   done	   on	   the	   control	   and	  pathologic	  arteries.	  Example	  of	  WB	  using	  antibodies	  against	  (A)	  :	  α-­‐smooth	  muscle	  actin	  (SMA)	  ;	  (B)	  :	  smooth	  muscle-­‐myosin	  heavy	  chain	  (SM-­‐MHC)	  ;	   (C)	  :	  calponin	  ;	   (D)	  :	  non	  muscle-­‐myosin	  heavy	  chain-­‐B	  (NM-­‐MHC-­‐
B).	  For	  each	  WB,	  tubulin	  was	  used	  as	  second	  antibody	  to	  normalize	  the	  results.	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Discussion	  The	  present	  work	  was	  undertaken	  to	  examine	  the	  proportion	  of	  cVSMC	  and	  sVSMC	  into	  the	  healthy	  and	  pathologic	  human	  blood	  vessel	  wall	  and	  characterize	  their	  phenotype.	  We	  took	  advantage	   of	   the	   availability	   of	   tissue	   samples	   of	   vascular	   lesions	   removed	   during	   the	  operations.	  	  VSMCs	  biology	  has	  been	  studied	  in	  vitro	  and	   in	  vivo	  extensively	  in	  the	  past	  50	  years	  since	  the	  method	  for	  SMCs	  culture	  was	  established.	  The	  concept	  of	  «	  phenotypical	  modulation	  »	  of	  SMCs	  was	  originated	  from	  the	  ultrastructural	  characterization	  of	  SMCs	  culture	  in	  1960s-­‐1970s,	   which	   has	   been	   summarized	   in	   the	   comprehensive	   review	   by	   Chamley-­‐Campbell	  and	   Ross.18	   The	   contractile	   SMCs	   are	   characterized	   by	   the	   cytoplasm	   largely	   filled	   with	  thick	   and	   thin	   myofilaments,	   while	   synthetic	   SMCs	   have	   few	   myofilaments	   but	   a	   larger	  amount	  of	  rough	  endoplasmic	  reticulum,	   free	  ribosomes	  and	  Golgi	  plasma.	  Depending	  on	  the	   method	   used	   during	   this	   work,	   the	   results	   were	   difficult	   to	   explain.	   Using	  immunohistochemistry	   analysis	   we	   found	   that	   α-­‐SMA	   was	   mostly	   expressed	   in	   control	  arteries,	  whereas	  NM-­‐MHC-­‐B	  in	  the	  pathologic	  ones.	  Using	  SM-­‐MHC	  and	  calponin,	  we	  found	  no	   significative	   differences	   in	   the	   expression	   of	   these	   proteins	   in	   the	   control	   and	   in	   the	  pathologic	  samples.	  Western	  blot	  analysis	  showed	  an	  inverse	  correlation	  between	  healthy	  and	   pathological	   samples	   as	   α-­‐SMA	   was	   more	   expressed	   in	   the	   pathological	   samples,	  whereas	  NM-­‐MHC-­‐B	  in	  the	  control	  group	  ;	  SM-­‐MHC	  and	  calponin	  were	  mostly	  expressed	  in	  the	  pathologic	  samples.	  If	  we	  think	  that	  stenotic	  lesions	  are	  mainly	  due	  to	  the	  proliferation	  of	   sVSMCs,	  we	   found	  a	  controversial	   result	   showing	   that	  SM-­‐MHC	   is	  mainly	  expressed	   in	  pathologic	   specimens.	   Indeed	   SM-­‐MHC	   is	   the	   most	   specific	   marker	   of	   differenciated	  cVSMCs	   identified	   to	   date.19	   Although	   extensive	   studies	   have	   identified	  mechanisms	   that	  control	   the	  process	  of	   SMCs	  phenotypic	   switching	   in	   cultured	   cells,8	   there	  are	   still	  major	  ambiguities	   regarding	   the	   definitive	   identification	   of	   altered	   VSMCs	   phenotypes	   during	  vascular	   remodelling,	   including	   vascular	   injury-­‐induced	   proliferation	   and	   atherosclerotic	  plaque	   progression	   since	   a	   key	   feature	   of	   this	   process	   is	   the	   loss	   of	   expression	   SMCs	  selective	   gene	   products	   such	   as	   SM-­‐MHC	   and	   α-­‐SMA.20	   It	   is	   now	   widely	   accepted	   that	  VSMCs	  have	  a	  phenotypic	  plasticity	  and	  that	  mature	  and	  cVSMCs	  can	  de-­‐differenciate	  into	  proliferative	   and	   synthetic	  VSMCs.	  However,	   this	  de-­‐differentiation	  process	  has	  not	  been	  directly	  demonstrated	  by	  tracking	  the	  fate	  of	  mature	  or	  contractile	  VSMCs.	  Indeed,	  there	  is	  a	  critical	  need	  for	  definitive	  in	  vivo	  VSMCs	  lineage	  tracking	  studies.20,21	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Tang	   et	   al	   recently	   published	   that	   the	   differentiation	   of	   multipotent	   vascular	   stem	   cells	  rather	   than	   the	   de-­‐differentiation	   of	   VSMCs,	   contributes	   to	   vascular	   remodelling	   and	  diseases.22	  The	  presence	  of	  large	  cells	  body	  in	  the	  neointima	  that	  secrete	  ECM	  and	  express	  lower	   levels	  of	   the	  smooth	  muscle-­‐specific	  contractile	  proteins	   is	  consistent	  with	   the	   fact	  that	  the	  de-­‐diffentiated	  cells	  is	  present	  in	  the	  neointima.23	  Our	  results	  of	  semi-­‐quantitative	  analysis	  of	  SM-­‐MHC	  and	  α-­‐SMA	  showed	  a	  high	  expression	  of	  these	  two	  markers	  of	  differentiated	  cells	  in	  the	  media	  of	  the	  vessels	  in	  the	  control	  group	  and	   also	   located	   in	   the	   subintimal	   space	   in	   the	   pathologic	   specimens.	   These	   cells	   are	  differentiated	   even	   if	   there	   were	   previously	   de-­‐differentiated.	   Nevertheless,	   they	  differentiated	   few	   days	   after	   the	   principal	   injury	   lesion.	   All	   the	   pathological	   specimens	  were	  harvested	  in	  patients	  with	  long	  lasting	  lesions.	  They	  have	  consistent	  stenotic	  lesions	  with	   already	   differentiated	   VSMCs.	   Shy	   et	   al	   showed	   that	   during	   the	   remodelling	   of	   an	  autologous	   vein	   graft,	   a	   proportion	   of	   neointimal	   cells	   derived	   from	   adventitial	  myofibroblasts.	  We	  did	  not	  find	  a	  high	  expression	  of	  VSMCs	  markers	  in	  the	  adventitial	  area,	  probably	   by	   the	   fact	   that	   this	   phenomenom	   occured	   in	   the	   beginning	   of	   the	   neointima	  formation.	  It	  has	  also	  been	  showed	  that	  an	  important	  degree	  of	  apoptosis	  takes	  place	  in	  the	  vein	  graft	  VSMCs,	  needing	  probably	   the	   recruitment	  of	  myofibroblasts.	  Unfortunately	   the	  smoothelin	  marker,	  which	  is	  specific	  for	  VSMCs	  was	  not	  expressed	  in	  the	  pathological	  and	  control	  vessels	  probably	  due	  to	  technical	  problem	  (data	  not	  shown).24	  A	   number	   of	   recent	   studies	   have	   provided	   evidence	   showing	   that	   circulating	   cells,	  presumably	  derived	  from	  bone	  marrow	  can	  contribute	  to	  neointima	  formation	  and	  repair	  the	  vascular	  injury.25	  Owens	  et	  al	  have	  found	  that	  the	  primary	  antibody	  employed	  in	  these	  studies	  cross	  reacts	  with	  a	  nonmuscle	   isoform	  of	  SM-­‐MHC,	  NM-­‐MHC-­‐B.8	  Frid	  et	  al	  used	  a	  panel	  of	  antibodies	  specific	  for	  different	  markers	  of	  VSMCs	  differentiation	  including	  α-­‐SMA,	  SM-­‐MHC,	   calponin	   to	   perform	   immunofluorescence	   labelling	   studies	   on	   cryosections	   of	  adult	  and	  fetal	  bovine	  main	  pulmonary	  arteries.	  In	  addition,	  they	  performed	  Western	  Blot	  analyses	   of	   these	   markers	   in	   three	   different	   layers	   of	   the	   adult	   bovine	   artery.	   They	  reported	  the	  presence	  of	  what	  they	  categorized	  as	  four	  distinct	  populations	  or	  clusters	  of	  VSMCs	   based	   on	   morphology,	   cell	   orientation,	   pattern	   of	   elastic	   lamellae	   and	  immunostaining	   patterns	   and	   speculated	   that	   these	   distinct	   populations	   may	   represent	  unique	  lineages	  that	  may	  serve	  different	  functions	  within	  the	  artierial	  media,	  and	  respond	  differently	  to	  pathophysiological	  stimuli.26	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The	   origin	   of	   VSMCs	   observed	   in	   the	   neointima	   formation	   is	   probably	   multiple.	   The	  perivascular	  myofibroblasts	  are	  able	  to	  translocate	  into	  the	  media	  and	  exhibit	  sustained	  α-­‐SMA	   expression.	   In	   the	   tunica	   media,	   mesenchymal	   stem	   cells	   (MSC)-­‐like	   cells	   can	   be	  isolated	   from	   VSMCs	   population,	   which	   express	   CD29	   and	   CD44,	   and	   have	   multilineage	  potential	   for	   osteogenic	   and	   chodrogenic	   differentiation.27,28	   In	   adventitia,	   Sca-­‐1+	  progenitors	  can	  diffenrentiate	  into	  VSMCs	  and	  contribute	  to	  atherosclerosis	  of	  vein	  grafts	  in	  ApoE-­‐deficient	  mice.29	  Furthermore,	  evidence	  exists	  that	  vascular	  endothelial	  cells	  (ECs)	  can	   be	   converted	   into	   MSC-­‐like	   cells	   by	   an	   activin-­‐like	   kinase-­‐2	   receptor-­‐dependant	  mechanism.30	   However,	   the	   characterization	   of	   these	   vascular	   progenitors	   have	   an	  important	  role	  in	  the	  generation	  of	  proliferative	  or	  synthetic	  VSMCs	  and	  the	  development	  of	  vascular	  diseases	  remain	  unclear.	  In	   summary,	   whereas	   we	   cannot	   rule	   out	   that	   SM-­‐MHC	   may	   be	   expressed	   at	   least	  transiently	   under	   certain	   circumstances	   in	   cells	   other	   than	   VSMCs	   in	   vivo,	   to	   our	  knowledge,	   conclusive	   evidence	   of	   SM-­‐MHC	   expression	   in	   a	   non-­‐VSMC	   in	   vivo	   does	   not	  exist,	  and,	  at	  present	  it	  is	  the	  most	  specific	  marker	  to	  discriminate	  the	  VSMC.8	  Contractile	   VSMC	   express	   many	   proteins	   such	   as	   α-­‐SMA,	   SM-­‐MHC,	   calponine	   h1,	   h-­‐caldesmon,	  smoothelin,	  etc.8	  	  While	  α-­‐SMA	  serves	  as	  a	  «	  general	  »	  marker	  for	  the	  identification	  of	  VSMCs,	  α-­‐SMA	  is	  also	  expressed	  by	  immature	  or	  modulated	  VSMCs.	  Furthermore	  other	  non-­‐SM	  cell	  types,	  called	  VSMC-­‐like,	  that	  share	  similar	  morphology	  and	  behaviors,	  such	  as	  myofibroblasts,	  can	  also	  express	  α-­‐SMA.31	   Indeed,	   activated	  myofibroblast	   and	   VSMCs	   common	  markers	  :	  α-­‐SMA,	  h1-­‐calponin,	  and	  possibly,	  SM-­‐MHC.	  These	  observations	  are	  not	  surprising.	   Indeed,	   it	  has	  been	  hypothesized	  that	   the	   fibroblats/myofibroblasts	  represent	  an	  alternative	  phenotype	  of	  the	  VSMCs	  and/or	  a	  progenitor/precursor	  of	  fully	  differenciated	  mature	  VSMCs.	  
α-­‐SMA	  and	  some	  other,	   is	  not	  unique	   to	   this	   cell	   type.	  Watch	  out	   false	  positive	  and	   false	  negative.32	   It	   is	   important	   to	   make	   a	   difference	   between	   differentiation	   markers	   and	   a	  lineage	  markers.	  One	  serve	  as	  indice	  of	  the	  relative	  state	  of	  diffenrenciation	  of	  VSMCs	  and,	  respectively,	   the	   others	   serve	   to	   identify	   VSMCs	   to	   the	   exclusion	   of	   all	   other	   cell	   types.	  Using	   this	   kind	   of	   categorization,	  α-­‐SMA	   found	   to	   be	   expressed	   by	   VSMCs	   an	   VSMC-­‐like	  cells	   and	   represents	   around	  40%	  of	   the	   total	   cell	   proteins,	   is	   not	   a	   good	   lineage	  marker	  because	  it	  is	  expressed	  by	  to	  many	  different	  cells.8	  Neointimal	   hyperplasia	   is	   a	   major	   obstacle	   to	   the	   long	   term	   success	   of	   percutaneous	  interventions	   as	   well	   as	   surgical	   therapies	   (e.g	   bypass	   grafting).	   The	   drug	   eluting	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technology	   showed	   promising	   result	   in	   peripheral	   arteries.	   Nevertheless	   it	   remains	   still	  many	   unknown	   biological	   mechanisms	   that	   trigger	   the	   proliferation	   of	   cells	   in	   the	  neointima	   followed	   by	   deposition	   of	   ECM.	   Defining	   the	   origin	   of	   neointimal	   VSMCs,	   the	  functional	   implications	   of	   interactions	   between	   resident	   VSMCs	   and	   infiltrating	   or	  circulating	   progenitor	   cells	   remain	   an	   important	   issue	   for	   the	   design	   of	   more	   effective	  therapeutics	  to	  control	  restenosis.	  	  
Conclusion	  The	   aim	   of	   our	   research	  was	   to	   quantify	   the	   proportion	   of	   cVSMCs	   into	   the	   healthy	   and	  pathologic	  human	  blood	  vessel	  wall	  and	  to	  characterize	  their	  phenotype.	  It	  showed,	  on	  one	  hand,	   no	   clear	   difference	   between	   stenotic	   and	   control	   arterial	   venous	   segments	   using	  semiquantitative	  assessement	  by	  immunohistochemistry.	  On	  the	  other	  hand,	  Western	  Blot	  analysis	   showed	  a	   significant	   expression	  of	  α-­‐SMA,	   calponin	  and	  SM-­‐MHC	   in	   the	  arteries	  with	   stenosis,	   while	   NM-­‐MHC-­‐B	   was	   mostly	   expressed	   in	   the	   arteries	   without	   lesions.	  Further	  studies	  are	  needed	   to	   track	   the	   lineage	  of	  VSMCs	   to	  understand	   the	  mechanisms	  leading	  to	  IH.	  	  
Guide	  of	  the	  Abbreviations	  
BV	  :	  Basilic	  Vein	  
CDK	  :	  Chronic	  Kidney	  Disease	  
CV	  :	  Cephalic	  Vein	  
CVD	  :	  Cardio-­‐Vascular	  Disease	  
DFA	  :	  Deep	  Femoral	  Artery	  
EC(s)	  :	  Endothelial	  Cell(s)	  
ECM	  :	  Extra-­‐Cellular	  Matrice	  
EIA	  :	  External	  Iliac	  Artery	  
GSV	  :	  Great	  Saphenous	  Vein	  
HE	  :	  Hematoxylin	  &	  Eosin	  stain	  
IH	  :	  Intimal	  Hyperplasia	  
MSC(s)	  :	  Mesenchymal	  Stem	  Cell(s)	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NM-­‐MHC(-­‐B)	  :	  Non	  Muscle-­‐Myosin	  Heavy	  Chain(-­‐B)	  
PBS	  :	  Sodium	  Perborate	  
PBS-­‐T	  :	  Phosphate	  Buffered	  Saline-­‐Tween	  
PG	  :	  Proteoglycans	  
PTA	  :	  Posterior	  Tibial	  Artery	  
RBP-­‐1	  :	  Retinol	  Binding	  Protein-­‐1	  
SD	  :	  Standard	  Deviation	  
SDS-­‐PAGE	  :	  Sodium	  Dodecyl	  Sulfate-­‐Polyacrilamide	  Gel	  Electrophoresis	  
SFA	  :	  Superficial	  Femoral	  Artery	  
α-­‐SMA	  :	  α-­‐Smooth	  Muscle	  Actin	  
SMC(s)	  :	  Smooth	  Muscle	  Cell(s)	  
SM-­‐MHC	  :	  Smooth	  Muscle-­‐myosin	  Heavy	  Chain	  
TFT	  :	  Tibio-­‐Fibular	  Trunk	  
TMB	  :	  Masson’s	  Trichrome	  stain	  
Tub	  :	  Tubulin	  
VGEL	  :	  Van	  Gieson’s	  stain	  
VSMC(s)	  :	  Vascular	  Smooth	  Muscle	  Cell(s)	  	  
cVSMC(s)	  :	  contractile	  Vascular	  Smooth	  Muscle	  Cell(s)	  
sVSMC(s)	  :	  synthetic	  Vascular	  Smooth	  Muscle	  Cell(s)	  
VWF	  :	  Von	  Willebrand	  Factor	  
WB	  :	  Western	  Blot	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